Besides, FZD5 antibodies also inhibited the growth of RNF43-mutant CRC-patient-derived organoids suggesting that FZD5 may be associated with RNF43 mutation across multiple cancer types, expanding the use of FZD5 antibody in cancer treatment [36]. Here, FZD5 is linked to colorectal carcinoma.